Comparison of prednisolone and lamivudine combined therapy with prednisolone monotherapy on carriers of hepatitis B virus with IgA nephropathy: a prospective cohort study
Authors:
- 12 June 2013
- journal article
- research article
- Published by Springer Nature in International Urology and Nephrology
- Vol. 46 (1) , 49-56
Abstract
Chronic hepatitis B virus (HBV) carrier status has a critical impact on clinical management of patients with IgA nephropathy (IgAN) who are treated with corticosteroids, because corticosteroids may enhance HBV replication. This study compared corticosteroids and antivirals combined therapy with corticosteroids monotherapy on patients of IgAN who were also HBV carriers. This was a prospective, open-label cohort study on Chinese adults of HBV inactive carriers with concurrent IgAN (proteinuria ≥3.5 g/day). The patients were self-assigned to combined therapy group (prednisolone + lamivudine) or monotherapy group (prednisolone). Prednisolone 1 mg/kg/day for 2 months, tapered gradually, duration 12 months. Lamivudine (100 mg/day) was administrated 2 weeks before starting prednisolone and maintained 6 months after prednisolone withdrawal. All patients were followed up for 18 months. Outcome measures were rates of complete remission of proteinuria (120 μ/L). Except 3 patients were lost to follow-up, 46 patients (29 of combined therapy group, 17 of monotherapy group) were included in the analysis. There were no differences in baseline characteristics of clinical and histopathological features between two groups (p > 0.05). At the end of follow-up, 19/29 (65.52 %) in combined therapy group and 9/17 (52.94 %) in monotherapy group achieved complete remission of proteinuria (p = 0.399), while 0/29 (0 %) and 2/17 (11.76 %) remained persistent massive proteinuria (p = 0.059). HBV reactivation and significant ALT elevation was 3/17 (17.65 %) of patients in monotherapy group, more than 0/29 (0 %) of combined therapy group (p = 0.019). Three HBV recurrent patients using prednisolone monotherapy were all male and young, with relatively short term of HBV infection history, HBV reactivation and severe liver impairment developed after 3 months of corticosteroids treatment, and daily proteinuria increased remarkably after prednisolone withdrawal. This study successfully treated with combined lamivudine and prednisolone in inactive HBV carriers with IgAN. We believe the combination of prednisolone and lamivudine was more efficacious than prednisolone alone in providing long-term viral suppression and liver enzyme normalization in inactive HBV carrier with IgAN.Keywords
This publication has 18 references indexed in Scilit:
- Comparison between steroid pulse therapy alone and in combination with tonsillectomy for IgA nephropathyInternational Urology and Nephrology, 2012
- Comparison of Steroids and Angiotensin Receptor Blockers for Patients with Advanced IgA Nephropathy and Impaired Renal FunctionAmerican Journal of Nephrology, 2011
- Tenofovir as a first line option for prophylaxis in a patient with hepatitis B virus associated nephrotic syndromeAnnals of Hepatology, 2011
- Treatment of hepatitis B virus-associated glomerulonephritis: A meta-analysisWorld Journal of Gastroenterology, 2010
- The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classificationKidney International, 2009
- The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibilityKidney International, 2009
- Hepatitis B treatment: Lessons for the nephrologistKidney International, 2006
- Predicting progression in IgA nephropathyAmerican Journal of Kidney Diseases, 2001
- Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failureKidney International, 1999
- Inflammation enhances cardiovascular risk and mortality in hemodialysis patientsKidney International, 1999